{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_17292", "batch_size": 260, "batch_pos": 53, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language without high-potency verbs, metaphors, superlatives, or critical alert phrases.", "method": "llm_batch", "batch_id": "batch_2_18200", "batch_size": 260, "batch_pos": 24, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment reports a factual plan and expectation ('late-stage testing would begin', 'pending results expected') which is not a moderate verb paired with realised scale/impact.", "method": "llm_batch", "batch_id": "batch_3_3044", "batch_size": 260, "batch_pos": 229, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment contains factual statements, not a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_16808", "batch_size": 260, "batch_pos": 219, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment reports a testing timeline but contains no explicit calming cue.", "method": "llm_batch", "batch_id": "batch_5_16820", "batch_size": 260, "batch_pos": 214, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser word combined with an explicit scale contrast.", "method": "llm_batch", "batch_id": "batch_6_15404", "batch_size": 260, "batch_pos": 181, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Segment contains no bare negation.", "method": "llm_batch", "batch_id": "batch_7_18388", "batch_size": 260, "batch_pos": 173, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes planned action/future possibility ('late-stage testing would begin in 2025'), a capability.", "method": "llm_batch", "batch_id": "batch_8_15428", "batch_size": 260, "batch_pos": 257, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
